Muscle Function After Lung Transplantation in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Sponsor
Rigshospitalet, Denmark (Other)
Overall Status
Unknown status
CT.gov ID
NCT03548857
Collaborator
(none)
20
1
21.3
0.9

Study Details

Study Description

Brief Summary

The purpose of the project is to investigate changes in the quadriceps muscle and cardiovascular regulation during exercise in relation to improved lung function after lung transplantation in patients with COPD.

Condition or Disease Intervention/Treatment Phase
  • Other: Lung transplantation

Detailed Description

Dysfunctional skeletal musculature of the lower limbs is related to low quality of life, exercise intolerance and higher mortality in patients with COPD. Limb muscle dysfunction in COPD consists of muscle atrophy and reduced muscle strength but also intra-muscular alterations in oxidative capacity and mitochondrial function are often present. Moreover, reduced blood flow to exercising muscle may also contribute to the muscle dysfunction in COPD. The mechanisms responsible for muscle dysfunction in COPD patients remain unclear but could be a consequence of reduced lung function, inflammation, medications or low physical activity. Loss of lung function with COPD is normally irreversible so the transition to near-normal lung function after lung transplantation is a unique model to investigate the adaptation of the limb muscle to improved lung function. Thus, the purpose of this project is to investigate the effect of lung transplantation on limb muscle function (mitochondrial function, oxidative enzyme capacity, fiber type distribution, oxygen delivery/uptake) and daily physical activity level in patients with COPD. The project has a translational focus on muscle dysfunction in COPD and uses methodologies from clinical medicine, integrative physiology and molecular biochemistry in order to gain knowledge of mechanisms behind limb muscle dysfunction and exercise intolerance in COPD.

Study Design

Study Type:
Observational
Anticipated Enrollment :
20 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Muscle Function After Lung Transplantation in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Actual Study Start Date :
Aug 20, 2018
Anticipated Primary Completion Date :
Apr 30, 2020
Anticipated Study Completion Date :
May 30, 2020

Arms and Interventions

Arm Intervention/Treatment
COPD patients

COPD patients on the waiting list for a lung transplantation

Other: Lung transplantation
Single or double lung transplantation in patients with COPD

Outcome Measures

Primary Outcome Measures

  1. Change in leg blood flow (mL/min) [Change from baseline at 6 months]

    Endothelium function will be evaluated during acute exercise (one legged kicking) by Flow doppler

  2. Change in 6 min walking test [Change from baseline at 6 months]

    Exercise capacity

  3. Change in health-related quality of life [Change from baseline at 6 months]

    Health-related quality of life will be assessed by total mean score of St. George's Respiratory Questionnaire (SGRQ) (2 parts,3 components questionnaire). Scores range from 0 to 100, with higher scores indicating more limitations. A minimum change in score of 4 units are considered clinically relevant.

  4. Change in health-related quality of life [Change from baseline at 6 months]

    Health-related quality of life will be assessed by mean score of a validated Danish version of the COPD Assessment Test (CAT). The CAT is a short 8-item questionnaire with scoring range of 0-40, where higher scores indicating more limitations. A change of 2 units suggests a meaningful difference.

Secondary Outcome Measures

  1. Change in skeletal muscle function [Change from baseline at 6 months]

    Muscle biopsy

  2. Change in blood volume [Change from baseline at 6 months]

    CO re-breathing method

  3. Change in capillarization of lung tissue [Change from baseline at 6 months]

    Transbronchial biopsy (only COPD patients)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • COPD with or without alpha 1-antitrypsin deficiency on the waiting list for a lung transplantation

  • Single or double lung transplantation

  • ≥ 18 years

  • Ability to give informed consent

Exclusion Criteria:
  • Retransplantation

  • Multiple-organ transplantation (heart-lung transplantation)

  • Musculoskeletal disorders which substantially inhibits physical activity

  • Need for crossmatching in connection with lung transplantation

  • Anticoagulant therapy before lung transplantation (except acetylsalicylic acid)

Contacts and Locations

Locations

Site City State Country Postal Code
1 the Centre for Physical Activity Research, Copenhagen University Hospital Copenhagen Denmark

Sponsors and Collaborators

  • Rigshospitalet, Denmark

Investigators

  • Principal Investigator: Ulrik Winning Iepsen, MD, PhD, Centre for Physical Activity Research, Copenhagen University Hospital, Copenhagen, Denmark

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Camilla Koch Ryrsø, Principle Investigator, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT03548857
Other Study ID Numbers:
  • H-17039327
First Posted:
Jun 7, 2018
Last Update Posted:
Dec 26, 2019
Last Verified:
Dec 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Camilla Koch Ryrsø, Principle Investigator, Rigshospitalet, Denmark
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 26, 2019